ADO and cancer: In agreement, in MDAMB231 cancer cells, ADO increased cells migration through the A2BR/AC/PKA/cAMP axis [66] and A2BR pharmacological inhibition decreased cell migration in human epithelial lung cancer cells and renal cancer cell lines [67,101].